Ipsen Confident in U.S. Neurology Push Despite Dysport Delay
This article was originally published in The Pink Sheet Daily
Executive Summary
Neither FDA’s REMS request nor the prospect of competing with Allergan’s Botox appears to be spoiling Ipsen’s plans to stake a U.S. neurology stronghold.